The U.S. FDA granted approval for Insmed’s Brinsupri (brensocatib), marking the first treatment for non-cystic fibrosis bronchiectasis (NCFB). This oral DPP1 inhibitor targets neutrophilic inflammation, a root cause of bronchiectasis exacerbations, and is expected to benefit an estimated 500,000 U.S. patients. Clinical trials demonstrated significant reductions in pulmonary exacerbations and extended time between flare-ups. Insmed plans competitive pricing strategies, with analysts forecasting multi-billion-dollar peak annual sales. Buoyed by the approval, Insmed’s valuation has risen sharply, underpinning a strong growth outlook fueled by Brinsupri, its existing products like Arikayce, and pipeline candidates in lung and neuromuscular diseases.